Position in PGEN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$26,322,919
+$10,242,359 QoQ
Shares Held
6,801,788
+76.8% QoQ
Ownership
1.91%
of shares outstanding
% of Portfolio
7.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Diametric Capital, LP holds $50,262,099 across 63 Biotechnology names. PGEN ranks #1 (52.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PGEN |
Precigen, Inc.
This page
|
6,801,788 | $26,322,919 | |
| 2 | ABEO |
Abeona Therapeutics Inc.
|
611,520 | $2,739,609 | |
| 3 | VKTX |
Viking Therapeutics, Inc.
|
63,896 | $2,079,175 | |
| 4 | SLNO |
Soleno Therapeutics Inc
|
57,832 | $1,936,215 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
15,000 | $1,458,750 | |
| 6 | ENLV |
Enlivex Ltd.
|
1,483,178 | $1,379,355 | |
| 7 | ABVX |
Abivax S.A.
|
10,000 | $1,113,500 | |
| 8 | OCUL |
Ocular Therapeutix, Inc
|
125,000 | $1,058,750 |
All Filings in PGEN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $26,322,919 | 6,801,788 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $16,080,560 | 3,847,024 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $3,205,210 | 974,228 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $475,780 | 335,057 | Shares | Defined | 2025-08-13 | |
| 2023-12-31 | $65,014 | 48,518 | Shares | Defined | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||